

## HRMC Medication Use Policy

<b>TITLE: HRMC HIV Post-Exposure Prophylaxis (PEP) guidelines*</b>		
EFFECTIVE DATE: 3/05	POLICY#: PN.09a	Page 1 of 1
REVIEW: 5/05, 5/06, 5/07, 5/08, 5/09, 5/10 REVISION: 5/05, 3/08, 7/09, 3/12/14 (AHC)	Created by: R. Thelin, PharmD Revised by: HRMC & AHC P&T	DISTRIBUTION: Nursing; Pharmacy

Refer to AHC 2.167 Health Care Worker Exposure to Blood and Body Fluids, Post Exposure Prophylaxis Policy

<https://intranet.adventisthealthcare.com/policiesandprocedures/Corporate/Human%20Resources%20-%20Corporate/Occupational%20Health/AHC%202.167.pdf>

### Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) Regimens

#### Preferred HIV PEP Regimen

Raltegravir (Isentress; RAL) 400 mg PO twice daily

+

Truvada, 1 PO once daily

(Tenofovir DF [Viread; TDF] 300 mg \_ emtricitabine [Emtriva; FTC] 200 mg)

#### Alternative Regimens

(Select one from the left column and one combination from the right column)

Raltegravir (Isentress; RAL)

Combivir (Zidovudine [Retrovir; ZDV; AZT] + lamivudine [Epivir; 3TC])

Kaletra (Lopinavir/ritonavir; LPV/RTV)

Zidovudine (Retrovir; ZDV; AZT) + emtricitabine (Emtriva; FTC)

Truvada (Tenofovir DF [Viread; TDF] + emtricitabine [Emtriva; FTC])

Reference: CDC occupational postexposure prophylaxis guidelines. Updated October 2014.

Available at <http://www.aidsinfo.nih.gov>